POS COMBO PANEL TYPE 34 N/A B1017-214

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a health professional,user faci report with the FDA on 2016-07-27 for POS COMBO PANEL TYPE 34 N/A B1017-214 manufactured by Beckman Coulter Inc.

Event Text Entries

[50910524] The customer provided panel data for the repeat panel tested on 06/30/2016 was reviewed by beckman national product support team. Data indicated linezolid (lzd) mic = 4 (susceptible). Processed data indicated heavy growth in the 1 and 2 wells and very light growth in the 4 well, however not enough to achieve the threshold. The data did not indicate any hardware, product, or set up issues. The same isolate was sent to beckman coulter for testing. Beckman technical support lab (tsl) noted on the growth plates that there appeared to be two different colony types. The isolate was set up multiple times on pos combo panel type 34 (pc34) panels lot 2017-01-22 and on frozen reference panels, manufactured following clsi recommendations. Linezolid results were inconsistent, with the isolate testing as lzd susceptible and resistant on multiple frozen reference panels and pc34 panels. The failure mode for the false susceptible linezolid interpretation could not be conclusively determined with the information available. The testing indicates a possible mixed culture or atypical isolate (potentially with variable plasmid-mediated resistance) which could be contributing to the discrepant results. (b)(4).
Patient Sequence No: 1, Text Type: N, H10


[50910565] The customer reported a false susceptible linezoid (lzd) result was obtained on pos combo panel type 34 lot 2017-01-22 for a staphylococcus capitis isolate. The isolate was a (b)(6). (b)(6) expected a resistant lzd interpretation for the isolate. The customer initial test of the isolate on (b)(6) 2016 obtained the correct identification of staphylococcus capitis and the lzd mic was 4 (susceptible). Repeat test of the same isolate performed on (b)(6) 2016 obtained the same results. The customer stated they used prompt method for both panel set-ups. The panels were visually verified by the customer and the customer agreed with the instrument reads. Customer confirmed panel qc and instrument diagnostics were all in range for both weeks the (b)(6) isolate was tested. There was no patient involved as this was a proficiency survey isolate.
Patient Sequence No: 1, Text Type: D, B5


MAUDE Entry Details

Report Number2919016-2016-00005
MDR Report Key5828313
Report SourceHEALTH PROFESSIONAL,USER FACI
Date Received2016-07-27
Date of Report2016-06-30
Date of Event2016-05-26
Date Mfgr Received2016-06-30
Device Manufacturer Date2016-01-22
Date Added to Maude2016-07-27
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Reporter OccupationOTHER HEALTH CARE PROFESSIONAL
Health Professional3
Initial Report to FDA3
Report to FDA3
Event Location3
Manufacturer ContactELIZABETH CHURCH
Manufacturer Street2040 ENTERPRISE BLVD
Manufacturer CityWEST SACRAMENTO CA 95691
Manufacturer CountryUS
Manufacturer Postal95691
Manufacturer Phone9163742457
Manufacturer G1BECKMAN COULTER INC
Manufacturer Street250 S. KRAEMER BLVD
Manufacturer CityBREA CA 92821
Manufacturer CountryUS
Manufacturer Postal Code92821
Single Use3
Previous Use Code3
Removal Correction NumberN/A
Event Type3
Type of Report3

Device Details

Brand NamePOS COMBO PANEL TYPE 34
Generic NameMICRO DILUTION PANEL
Product CodeLTT
Date Received2016-07-27
Model NumberN/A
Catalog NumberB1017-214
Lot Number2017-01-22
Device Expiration Date2017-01-22
OperatorOTHER HEALTH CARE PROFESSIONAL
Device AvailabilityN
Device Eval'ed by MfgrR
Device Sequence No1
Device Event Key0
ManufacturerBECKMAN COULTER INC
Manufacturer Address2040 ENTERPRISE BLVD WEST SACRAMENTO CA 95691 US 95691


Patients

Patient NumberTreatmentOutcomeDate
10 2016-07-27

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.